Evidence map›Paper›PMID 40282947›Full record

ReviewMedicina (Kaunas, Lithuania)2025

Quercetin as a Potential Therapeutic Agent for Malignant Melanoma-A Review of Current Evidence and Future Directions.

Teodora Hoinoiu, Victor Dumitrascu, Daniel Pit, David-Alexandru Schipor, Madalina Jabri-Tabrizi, Bogdan Hoinoiu, David Emanuel Petreuș, Corina Seiman

Abstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Teodora HoinoiuDepartment of Clinical Practical Skills, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Sq. Nr. 2, 300041 Timisoara, Romania.ORCID 0000-0001-7753-7621
Victor DumitrascuDepartment of Pharmacology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Daniel PitDepartment of Clinical Practical Skills, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Sq. Nr. 2, 300041 Timisoara, Romania.ORCID 0009-0005-3386-8468
David-Alexandru SchiporFaculty of Chemistry, Biology, Geography, West University of Timisoara, Pestalozzi 16, 300115 Timisoara, Romania.
Madalina Jabri-TabriziDepartment of Clinical Practical Skills, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Sq. Nr. 2, 300041 Timisoara, Romania.
Bogdan HoinoiuDepartment of Oral Rehabilitation and Dental Emergencies, Faculty of Dentistry, "Victor Babes" University of Medicine and Pharmacy, P-ta Eftimie Murgu 2, 300041 Timisoara, Romania.ORCID 0000-0002-5217-7655
David Emanuel PetreușDepartment of Chemistry, Faculty of Chemistry, Biology, Geography, West University of Timisoara, Pestalozzi 16, 300115 Timisoara, Romania.ORCID 0009-0004-8508-6444
Corina SeimanDoctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoplastic disorders, particularly malignant carcinomas, are complex systemic diseases characterized by unregulated cellular proliferation, the invasion of adjacent tissues, and potential metastasis to distant bodily sites. Among the diverse spectrum of cancer subtypes, malignant melanoma is a highly aggressive form of cutaneous cancer originating in melanocytes, the pigment-producing cells resident in the skin. This malignancy is distinguished by its rapid and uncontrolled growth, as well as its propensity for metastasis to vital organs, thereby posing significant challenges to therapeutic intervention and prognostication. Early detection of melanoma is crucial for optimizing patient outcomes, as diagnosis at an advanced stage often yields a poor prognosis and limited treatment options. Diagnostic modalities for melanoma encompass comprehensive clinical evaluations by dermatologists; radiological imaging techniques such as ultrasonography, magnetic resonance imaging (MRI), computed tomography (CT) scans; and excisional biopsies for accurate histopathological assessment. Malignant melanoma is typically treated with surgery to remove the tumor, followed by immunotherapy to enhance the immune response, targeted therapy for tumors with specific genetic mutations, chemotherapy for advanced stages, radiation therapy to manage metastasis, and other adjunct therapies. This review presents the properties and possible adjunct therapeutic effects against malignant melanoma of quercetin found in the literature and explores, based on the observed physicochemical properties and biological activity, its potential development as a topical formulation for cutaneous application. Quercetin is a naturally occurring flavonoid compound abundant in various plant-based food sources, including apples, onions, berries, and citrus fruits, and has exhibited promising antiproliferative, antioxidant, and anticancer properties. Its distinctive biochemical structure enables quercetin to effectively neutralize reactive oxygen species and modulate key carcinogenic pathways, thereby rendering it a potential candidate for therapeutic intervention in managing malignant tumors, including melanoma.

Indexed as

MelanomaQuercetinSkin NeoplasmsAntineoplastic AgentsCutaneous Malignant MelanomaHumansAntineoplastic AgentsQuercetinmelanomaquercetinskin cancerwound healing

Identifiers

PMID40282947
PMCPMC12028657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.